Skip to main content

Advertisement

Table 1 Protocol reproducibility with the optimized clinical-grade compatible conditions using buffy coats from eight donor pairs

From: Generation of donor-specific Tr1 cells to be used after kidney transplantation and definition of the timing of their in vivo infusion in the presence of immunosuppression

  CD14+ purity (%) DC-10 yield (%) CD4+ purity (%) T10-cell yield (%) Donor-specific anergy (%)
Mean 95 13 98 53 80
SD 3 6 1 31 10
Range 90–99 4–21 97–99 17–123 63–94
CV 3.3 47.3 0.9 59.0 14.6
  1. DC-10 tolerogenic dendritic cells, SD standard deviation, CV coefficient of variation